[go: up one dir, main page]

CY1120427T1 - Ρυθμιστες υποδοχεα σφιγγοσινης 1 φωσφορικης και μεθοδοι χειρομορφης συνθεσης - Google Patents

Ρυθμιστες υποδοχεα σφιγγοσινης 1 φωσφορικης και μεθοδοι χειρομορφης συνθεσης

Info

Publication number
CY1120427T1
CY1120427T1 CY20181100376T CY181100376T CY1120427T1 CY 1120427 T1 CY1120427 T1 CY 1120427T1 CY 20181100376 T CY20181100376 T CY 20181100376T CY 181100376 T CY181100376 T CY 181100376T CY 1120427 T1 CY1120427 T1 CY 1120427T1
Authority
CY
Cyprus
Prior art keywords
methods
compounds
sphere
chronic
phosphoric
Prior art date
Application number
CY20181100376T
Other languages
English (en)
Inventor
Esther Martinborough
Marcus F. Boehm
Adam Richard Yeager
Junko Tamiya
Liming Huang
Enugurthi Brahmachary
Manisha Moorjani
Original Assignee
Celgene International Ii Sàrl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene International Ii Sàrl filed Critical Celgene International Ii Sàrl
Publication of CY1120427T1 publication Critical patent/CY1120427T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Παρέχονται ενώσεις που εκλεκτικώς ρυθμίζουν τον υποδοχέα σφιγγοσίνης 1 φωσφορικής συμπεριλαμβανομένων ενώσεων που ρυθμίζουν υπότυπο 1 του SIP υποδοχέα. Παρέχονται μέθοδοι χειρόμορφης σύνθεσης τέτοιων ενώσεων. Χρήσεις, μέθοδοι θεραπείας ή αποτροπής και μέθοδοι παρασκευής εφευρετικών συνθέσεων, που συμπεριλαμβάνουν εφευρετικές ενώσεις, παρέχονται σε σχέση με τη θεραπεία ή την αποτροπή ασθενειών, εσφαλμένων καταστάσεων και διαταραχών για τις οποίες ενδείκνυται ιατρικώς ρύθμιση του υποδοχέα σφιγγοσίνης 1 φωσφορικής.
CY20181100376T 2009-11-13 2018-04-04 Ρυθμιστες υποδοχεα σφιγγοσινης 1 φωσφορικης και μεθοδοι χειρομορφης συνθεσης CY1120427T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26128209P 2009-11-13 2009-11-13
US26247409P 2009-11-18 2009-11-18
PCT/US2010/056757 WO2011060389A1 (en) 2009-11-13 2010-11-15 Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis

Publications (1)

Publication Number Publication Date
CY1120427T1 true CY1120427T1 (el) 2019-07-10

Family

ID=43992104

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100376T CY1120427T1 (el) 2009-11-13 2018-04-04 Ρυθμιστες υποδοχεα σφιγγοσινης 1 φωσφορικης και μεθοδοι χειρομορφης συνθεσης

Country Status (25)

Country Link
US (3) US8357706B2 (el)
EP (1) EP2498611B1 (el)
JP (1) JP5988379B2 (el)
KR (1) KR101781233B1 (el)
CN (1) CN102724880B (el)
AU (1) AU2010320041B2 (el)
BR (1) BR112012011430A8 (el)
CA (1) CA2780433C (el)
CY (1) CY1120427T1 (el)
DK (1) DK2498611T3 (el)
EA (1) EA023183B1 (el)
ES (1) ES2665461T3 (el)
HR (1) HRP20180527T1 (el)
HU (1) HUE036391T2 (el)
IL (1) IL219690B (el)
LT (1) LT2498611T (el)
MX (1) MX2012005562A (el)
MY (1) MY160907A (el)
NZ (1) NZ599913A (el)
PH (1) PH12012500938A1 (el)
PL (1) PL2498611T3 (el)
PT (1) PT2498611T (el)
RS (1) RS57070B1 (el)
SI (1) SI2498611T1 (el)
WO (1) WO2011060389A1 (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012500938A1 (en) * 2009-11-13 2016-09-16 Receptos Llc Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
CA2986521C (en) 2009-11-13 2020-06-30 Celgene International Ii Sarl Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
ES2758841T3 (es) * 2011-05-13 2020-05-06 Celgene Int Ii Sarl Moduladores heterocíclicos selectivos del receptor de la esfingosina-1-fosfato
CN103251950B (zh) * 2012-02-16 2018-10-02 中国人民解放军军事科学院军事医学研究院辐射医学研究所 S1p受体调节剂防治肠型放射病及放射性肠炎的用途
EP2920150B1 (en) 2012-11-16 2017-07-19 F. Hoffmann-La Roche AG Process for the preparation of 2-trifluoromethyl isonicotinic acid and esters
BR112015019794B1 (pt) 2013-02-20 2022-09-13 Lg Chem, Ltd Composto, composição farmacêutica, agonista do receptor de esfingosina-1-fosfato, e, uso de um composto
EP3062792A1 (en) * 2013-11-01 2016-09-07 Celgene International II Sarl Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith
SI3373931T1 (sl) 2015-11-13 2023-02-28 Oppilan Pharma Ltd. Heterociklične spojine za zdravljenje bolezni
WO2017109095A1 (en) * 2015-12-22 2017-06-29 AbbVie Deutschland GmbH & Co. KG Fused (hetero)cyclic compounds as s1p modulators
WO2017190107A1 (en) * 2016-04-29 2017-11-02 Board Of Regents, The University Of Texas System Sigma receptor binders
CN109661391B (zh) * 2016-07-22 2022-04-19 南京明德新药研发有限公司 S1p1激动剂及其应用
CN106749213B (zh) * 2016-11-25 2019-07-02 济南大学 一种具有1,2,4-恶二唑结构的吲哚衍生物及制备方法和在制备抗菌药物中的应用
CN108727291A (zh) * 2017-04-21 2018-11-02 宁波爱诺医药科技有限公司 奥扎莫德及其中间体的制备方法
CN108727292A (zh) * 2017-04-21 2018-11-02 宁波爱诺医药科技有限公司 一种奥扎莫德及其中间体的制备方法
AR116479A1 (es) 2018-09-25 2021-05-12 Quim Sintetica S A Intermediarios para la síntesis de ozanimod y procedimiento para la preparación del mencionado agonista del receptor de esfingosina-1-fosfato y de dichos intermediarios
CN110256288A (zh) * 2019-05-13 2019-09-20 苏州山青竹生物医药有限公司 一种制备(s)-1-氨基-2,3-二氢-1h-茚-4-甲腈的方法
CN112062785B (zh) * 2019-06-11 2023-06-27 广东东阳光药业有限公司 奥扎莫德及其中间体的制备方法
US20230055568A1 (en) 2020-02-06 2023-02-23 Mitsubishi Tanabe Pharma Corporation Therapeutic agent for myalgic encephalomyelitis/chronic fatigue syndrome
WO2021175225A1 (zh) * 2020-03-04 2021-09-10 南京明德新药研发有限公司 三环类化合物及其应用
WO2024246174A1 (en) 2023-05-31 2024-12-05 Química Sintética, S.A. Amorphous and crystalline form of ozanimod hydrochloride

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479544A (en) 1974-02-07 1977-07-13 American Cyanamid Co 1,2,3,4-tetrahydro-1-naphthylurea derivatives their preparation and their use
FR2628103B1 (fr) 1988-03-03 1991-06-14 Roussel Uclaf Nouveaux esters pyrethrinoides portant un noyau indanyle, leur procede de preparation et leur application comme pesticides
US5039802A (en) 1990-04-18 1991-08-13 Merck & Co., Inc. Arylation process for preparation of chiral catalysts for ketone reduction
EP0508425A1 (en) 1991-04-12 1992-10-14 Schering Corporation Bicyclic amides as inhibitors of acyl-coenzyme a: cholesterol acyl transferase
GB2290790A (en) * 1994-06-30 1996-01-10 Merck & Co Inc Asymmetric synthesis of 6-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes
HUP0100939A3 (en) 1998-01-23 2002-06-28 Sankyo Company Ltd Chuo Ku Spiropiperidine derivatives, medicaments containing them and their use
US20040058894A1 (en) 2002-01-18 2004-03-25 Doherty George A. Selective S1P1/Edg1 receptor agonists
US7220734B2 (en) 2002-12-20 2007-05-22 Merck & Co., Inc. 1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles as Edg receptor agonists
CN104056278B (zh) * 2003-04-11 2017-01-18 Ptc 治疗公司 1,2,4‑噁二唑苯甲酸化合物
AU2004277947A1 (en) * 2003-10-01 2005-04-14 Merck & Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as S1P receptor agonists
EP1697333A4 (en) * 2003-12-17 2009-07-08 Merck & Co Inc 3,4-DISUSBSTITUTED PROPANOIC CARBOXYLATES AS S1P RECEPTOR AGONISTS (EDG)
US7585881B2 (en) 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US20060173183A1 (en) 2004-12-31 2006-08-03 Alantos Pharmaceuticals, Inc., Multicyclic bis-amide MMP inhibitors
EP1851188A1 (en) * 2005-02-22 2007-11-07 Teva Pharmaceutical Industries Limited Improved process for the synthesis of enantiomeric indanylamine derivatives
KR100667075B1 (ko) 2005-07-22 2007-01-10 삼성에스디아이 주식회사 주사 구동부 및 이를 포함하는 유기 전계발광 표시장치
US7902336B2 (en) 2005-12-21 2011-03-08 Joseph Gabriele Catecholamine regulated protein
JP2009539762A (ja) 2006-03-13 2009-11-19 ファイザー・プロダクツ・インク Ｈ３受容体のテトラリン拮抗薬
US20080009534A1 (en) 2006-07-07 2008-01-10 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
JP2010513283A (ja) 2006-12-15 2010-04-30 アボット・ラボラトリーズ 新規なオキサジアゾール化合物
WO2008106226A2 (en) 2007-02-28 2008-09-04 Rib-X Pharmaceuticals, Inc. Macrolide compounds and methods of making and using the same
WO2009131090A1 (ja) 2008-04-21 2009-10-29 旭化成ファーマ株式会社 アミノ酸化合物
SI2291080T1 (sl) * 2008-05-14 2015-11-30 The Scripps Research Institute Novi modulatorji sfingosinskih fosfatnih receptorjev
WO2011005290A1 (en) 2009-06-23 2011-01-13 Arena Pharmaceuticals, Inc. Disubstituted oxadiazole derivatives useful in the treatment of autoimmune and inflammatory disorders
CA2986521C (en) 2009-11-13 2020-06-30 Celgene International Ii Sarl Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
PH12012500938A1 (en) 2009-11-13 2016-09-16 Receptos Llc Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
WO2011060391A1 (en) 2009-11-13 2011-05-19 Receptos, Inc. Selective heterocyclic sphingosine 1 phosphate receptor modulators
EP2766020A4 (en) 2011-10-12 2015-04-01 Teva Pharma TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD

Also Published As

Publication number Publication date
AU2010320041A1 (en) 2012-05-31
EP2498611B1 (en) 2018-01-10
DK2498611T3 (en) 2018-04-16
US9394264B2 (en) 2016-07-19
PT2498611T (pt) 2018-04-13
US8357706B2 (en) 2013-01-22
MY160907A (en) 2017-03-31
US20150299150A1 (en) 2015-10-22
CN102724880A (zh) 2012-10-10
EP2498611A4 (en) 2013-05-22
WO2011060389A1 (en) 2011-05-19
AU2010320041B2 (en) 2015-04-02
NZ599913A (en) 2014-08-29
JP5988379B2 (ja) 2016-09-07
MX2012005562A (es) 2012-10-05
PH12012500938A1 (en) 2016-09-16
US20130196966A1 (en) 2013-08-01
EA023183B1 (ru) 2016-05-31
RS57070B1 (sr) 2018-06-29
KR20120099070A (ko) 2012-09-06
EP2498611A1 (en) 2012-09-19
PL2498611T3 (pl) 2018-07-31
HUE036391T2 (hu) 2018-07-30
US20110178056A1 (en) 2011-07-21
EA201290331A1 (ru) 2012-12-28
CA2780433C (en) 2018-01-02
CA2780433A1 (en) 2011-05-19
HRP20180527T1 (hr) 2018-05-04
KR101781233B1 (ko) 2017-09-22
BR112012011430A8 (pt) 2017-12-26
BR112012011430A2 (pt) 2015-10-06
IL219690A0 (en) 2012-07-31
LT2498611T (lt) 2018-04-25
CN102724880B (zh) 2016-09-14
JP2013510883A (ja) 2013-03-28
ES2665461T3 (es) 2018-04-25
SI2498611T1 (en) 2018-05-31
IL219690B (en) 2019-08-29

Similar Documents

Publication Publication Date Title
CY1120427T1 (el) Ρυθμιστες υποδοχεα σφιγγοσινης 1 φωσφορικης και μεθοδοι χειρομορφης συνθεσης
CY1124121T1 (el) Εκλεκτικοι ρυθμιστες υποδοχεα σφιγγοσινης 1 φωσφορικης και μεθοδοι χειρομορφικης συνθεσης
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
CY1121170T1 (el) Νεες ενωσεις ως ρυθμιστες πρωτεϊνικων κινασων
EA201001253A1 (ru) N,n-дизамещенные аминоалкилбифенилы в качестве антагонистов рецепторов простагландина d
EP2498609A4 (en) SELECTIVE HETEROCYCLIC SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORS
CY1119766T1 (el) Νεοι ρυθμιστες κινασης βενζοπυρανιου
EA201100133A1 (ru) Антагонисты рецепторов простагландина d
BR112012020273A2 (pt) Compostos de pirazolopiridina, pirazolopirazina, pirazolopirimidina, pirazolotiofeno e pirazolotiazol como pontencializadores alostéricos de mglur4, composições e métodos de tratamento de disfunção neurológica
UA116774C2 (uk) Інгібітори серин/треонінкінази
EA201490922A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
PA8836101A1 (es) Inhibidores alfa7 nicotínicos del receptor de acetilcolina
EA201071245A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс
EA200901144A1 (ru) Ингибиторы киназы pim и способы их применения
MX339937B (es) Compuestos y composiciones como inhibidores de la quinasa c-kit.
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
PH12014500351B1 (en) COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS
EA201290894A1 (ru) Азетидиновые производные пиперидин-4-ила как ингибиторы jak1
EP2560660A4 (en) THERAPIES BASED ON CHEMOSOUS RECEPTOR LIGANDS
UA111075C2 (uk) Триазолопіридинові сполуки як інгібітори кінази рім
BR112015026021A2 (pt) terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer
WO2012158550A3 (en) Selective heterocyclic sphingosine 1 phosphate receptor modulators
CY1115725T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων
MX356813B (es) Derivados de hidantoina utiles como inhibidores de kv3.
MX2009011952A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.